Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Zentalis Pharmaceuticals, Inc.

NASDAQ: ZNTL · Life Sciences · 2 alerts · CIK 1725160

Share price
$1.60Close, Nov 16
Market cap
$157M
Shares outstanding
98.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zentalis Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:12 PM ET 10-Q
Financial Results

Zentalis Pharmaceuticals Q3 2026 Results: Net Loss of $28.8M, Loss Widens

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, azenosertib (ZN-c3), for various oncology indications including ovarian cancer. As of November 4, 2026, the company had 98,265,863 shares of common stock outstanding and is prioritizing its Phase 3 ASPENOVA and Phase 2 DENALI trials.

Key figure
Net loss $28.8M
4:10 PM ET 8-K
Financial Results

Zentalis Pharmaceuticals Financial Results

Zentalis Pharmaceuticals reported third quarter 2026 financial results and provided updates on its clinical pipeline, specifically the azenosertib program for ovarian cancer. The company expects a topline readout from the DENALI trial in the first half of 2027 and reported a cash runway extending into the first half of 2028.

“Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved.”

Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals

“With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer.”

Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.